Van Eck Associates Corp 89bio, Inc. Transaction History

Van Eck Associates Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$17.42 - $28.0 $57,747 - $92,820	-3,315 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$20.22 - $26.73 $990 - $1,309	49 Added 1.5%	3,315 $78,000
Q4 2020 Feb 09, 2021	BUY	$23.16 - $28.08 $35,156 - $42,625	1,518 Added 86.84%	3,266 $80,000
Q3 2020 Nov 12, 2020	BUY	$24.34 - $38.82 $900 - $1,436	37 Added 2.16%	1,748 $45,000
Q2 2020 Aug 10, 2020	BUY	$19.93 - $31.2 $34,100 - $53,383	1,711 New	1,711 $34,000

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.